Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook



ACMG recommends caution on genome editing

06 February 2017

By Rachel Siden

Appeared in BioNews 887

The American College of Medical Genetics and Genomics (ACMG) has published a statement recommending caution over the clinical application of genome editing.

The college's 'points to consider' highlight technological and ethical concerns that it believes should be addressed before genome-editing technology can be used to treat genetic diseases in humans.

'Our goal in this statement is to draw attention to the opportunities for the treatment of genetic conditions, some of the challenges that are being actively addressed, and the ongoing concern about even greater challenges associated with germline, as opposed to somatic, genome editing,' said ACMG President Gerald Feldman.

While developments in genome editing are occurring rapidly, the technology is not perfect, and the ACMG recommends rigorous medical review of the clinical applications. For treating somatic cells in patients, this involves ensuring that the disease-causing variant is corrected to a form that ends the disease, that no other variants are created, and that cells do not pick up epigenetic changes that could create abnormal function when transplanted back into the individual.

For altering the genome of human embryos, this involves preventing off-target effects, ensuring that editing a disease-causing variant has no harmful epigenetic effects, and considering the potential genetic impact on future generations.

The ACMG also addresses ethical concerns about the effect on society of clinical genome editing. It will need to be decided which variants – highly impactful disease-causing variants, minimally impactful disease-causing variants, or non-disease variants – should or should not be subject to genome editing.

The statement concludes: 'In light of these potentially serious and far-reaching concerns, the ACMG Board of Directors believes that genome editing in the human embryo is premature and should be subject to vigorous ethical debate and further refinement of technological issues.

'The ACMG will appoint an ad hoc committee to recommend specific areas where it can contribute to this debate.'


20 February 2017 - by Dr Rachel Huddart 
An influential advisory group has given cautious support to the idea of making heritable changes to the human genome in order to treat or prevent disease...

16 May 2016 - by Anneesa Amjad 
An international body representing stem cell scientists has included human genome editing in its updated guidance on the manipulation of stem cells and their use in therapy...
01 February 2016 - by Ayala Ochert 
The Human Fertilisation and Embryology Authority has granted the first licence to a UK researcher to edit the genomes of human embryos...
07 December 2015 - by Dr Jane Currie 
An international summit has agreed conditions under which human genome editing, using techniques like CRISPR, should proceed...
26 May 2015 - by Ceri Durham 
Scientists will gather in the USA later this year to produce ethical guidelines on the use of human gene-editing techniques such as CRISPR/Cas9....

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust


Public Conference
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation